RxDoctor Payments Data

Carlos Reyes

Internal Medicine · San Juan, PRNPI 1992909329

Payments from drug & device makers

$247in general payments, 2019–2025

Across 12 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$71
  • Novo Nordisk$38
  • Pfizer$32
  • Biohaven Pharmaceuticals, Inc.$32
  • Eisai Inc.$29
  • Amgen$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$247100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Esperion Therapeutics, Inc.1$71
Novo Nordisk2$38
Pfizer2$32
Biohaven Pharmaceuticals, Inc.2$32
Eisai Inc.2$29
Amgen1$15
Boehringer Ingelheim1$14
Zyla Life Sciences, Inc.1$14

How this compares

$247 in reported general payments places this provider in the 25th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,796
Medicare patients
30
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$125,940
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$50,727
InvokanaCanagliflozin55$44,778
Tresiba Flextouch U-100Insulin Degludec70$41,581
XareltoRivaroxaban35$40,528
TresibaInsulin Degludec42$30,245
DescovyEmtricitabine/Tenofov Alafenam11$23,741
OzempicSemaglutide16$20,250
Spiriva HandihalerTiotropium Bromide29$20,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,652
SymbicortBudesonide/Formoterol Fumarate35$10,548
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$9,993
Albuterol Sulfate HfaAlbuterol Sulfate254$8,373
Advair HfaFluticasone Propion/Salmeterol22$8,127
Rosuvastatin Calcium1,067$6,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$125,940120 claims
Novo NordiskTresiba, Ozempic, Novolog$38$54,67079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →